MA51733A - Composition contraceptive présentant des effets cardiovasculaires réduits - Google Patents

Composition contraceptive présentant des effets cardiovasculaires réduits

Info

Publication number
MA51733A
MA51733A MA051733A MA51733A MA51733A MA 51733 A MA51733 A MA 51733A MA 051733 A MA051733 A MA 051733A MA 51733 A MA51733 A MA 51733A MA 51733 A MA51733 A MA 51733A
Authority
MA
Morocco
Prior art keywords
cardiovascular effects
contraceptive composition
reduced cardiovascular
reduced
contraceptive
Prior art date
Application number
MA051733A
Other languages
English (en)
French (fr)
Inventor
Maud Jost
Glwadys Rausin
Original Assignee
Estetra Sprl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Estetra Sprl filed Critical Estetra Sprl
Publication of MA51733A publication Critical patent/MA51733A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
MA051733A 2018-02-07 2019-02-07 Composition contraceptive présentant des effets cardiovasculaires réduits MA51733A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18155571 2018-02-07
EP18160586 2018-03-07

Publications (1)

Publication Number Publication Date
MA51733A true MA51733A (fr) 2020-12-16

Family

ID=65278388

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051733A MA51733A (fr) 2018-02-07 2019-02-07 Composition contraceptive présentant des effets cardiovasculaires réduits

Country Status (20)

Country Link
EP (2) EP4140489A1 (https=)
JP (2) JP2021513507A (https=)
KR (1) KR102717921B1 (https=)
CN (2) CN111683664A (https=)
AU (1) AU2019219070B2 (https=)
CA (2) CA3178181A1 (https=)
CL (1) CL2020002017A1 (https=)
EC (1) ECSP20054822A (https=)
GE (2) GEAP202215414A (https=)
IL (1) IL276584B2 (https=)
JO (1) JOP20200169A1 (https=)
MA (1) MA51733A (https=)
NZ (1) NZ766027A (https=)
PH (1) PH12020500601A1 (https=)
PY (1) PY1908892A (https=)
SG (1) SG11202007163WA (https=)
TW (1) TWI845496B (https=)
UA (1) UA126746C2 (https=)
UY (1) UY38075A (https=)
WO (1) WO2019154899A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116077454A (zh) 2015-06-18 2023-05-09 埃斯特拉有限责任公司 含雌四醇组分的口腔分散剂量单位
HUE054589T2 (hu) 2015-06-18 2021-09-28 Estetra Sprl Szájban diszpergálódó esztetrol tartalmú tabletta
RS61777B1 (sr) 2015-06-18 2021-06-30 Estetra Sprl Oralno-disperzibilna tableta koja sadrži estetrol
MD3310333T2 (ro) 2015-06-18 2020-06-30 Estetra Sprl Unitate de dozare orodispersabilă care conține un component estetrol
CA3178291A1 (en) 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
DK3781171T3 (da) 2018-04-19 2022-05-02 Estetra Srl Sammensætninger og deres anvendelser til lindring af menopause-associerede symptomer
TWI801561B (zh) 2018-04-19 2023-05-11 比利時商依思特拉私人有限責任公司 化合物及其用於緩解絕經相關症狀的用途
HU231240B1 (hu) 2019-09-03 2022-04-28 Richter Gedeon Nyrt. Ipari eljárás nagytisztaságú ösztetrol hatóanyag előállítására
TWI893101B (zh) * 2020-04-16 2025-08-11 比利時商埃斯特拉有限責任公司 具有降低之副作用之避孕組成物
WO2022248733A1 (en) 2021-05-28 2022-12-01 Neuralis Sa Use of estetrol in treatment of respiratory infection diseases

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4344405C2 (de) 1993-12-24 1995-12-07 Marika Dr Med Ehrlich Ovulationshemmendes Mittel und Verfahren zur hormonalen Kontrazeption
EP1390042B1 (en) * 2001-05-23 2007-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
EP1535618A1 (en) * 2003-11-26 2005-06-01 Schering Aktiengesellschaft Pharmaceutical preparation for continuous hormonal treatment over a period of longer than 21-28 days comprising two estrogen and/or progestin compositions
EP2432474A1 (de) * 2009-05-22 2012-03-28 Bayer Pharma Aktiengesellschaft Arzneimittel zur oralen verabreichung, enthaltend mindestens ein estrogen und/oder mindestens ein gestagen und mindestens einen probiotischen bakterien-stamm
WO2012055840A1 (en) * 2010-10-28 2012-05-03 Bayer Pharma Aktiengesellschaft Composition and preparation for treatment of dysmenorrhea and menstrual pain and use of a hormonal agent and a zinc salt for treatment of menstrual disorders
NO3079671T3 (https=) * 2013-12-12 2018-03-24
CA3178291A1 (en) * 2016-08-05 2018-04-12 Estetra Srl Method for the management of dysmenorrhea and menstrual pain
KR102780201B1 (ko) 2016-10-28 2025-03-12 에스테트라, 소시에떼 아 레스폰서빌리떼 리미떼 월경통 및 생리통의 관리방법

Also Published As

Publication number Publication date
EP3749327A1 (en) 2020-12-16
EP4140489A1 (en) 2023-03-01
CN115429806A (zh) 2022-12-06
JP7651645B2 (ja) 2025-03-26
AU2019219070B2 (en) 2024-12-19
CN111683664A (zh) 2020-09-18
CA3178181A1 (en) 2019-08-15
CL2020002017A1 (es) 2020-12-04
WO2019154899A1 (en) 2019-08-15
IL276584B1 (en) 2024-06-01
KR102717921B1 (ko) 2024-10-16
TWI845496B (zh) 2024-06-21
UY38075A (es) 2019-10-01
ECSP20054822A (es) 2020-12-31
AU2019219070A1 (en) 2020-09-24
TW202011967A (zh) 2020-04-01
CA3089804A1 (en) 2019-08-15
PY1908892A (es) 2019-10-15
SG11202007163WA (en) 2020-08-28
GEAP202215414A (en) 2022-04-25
PH12020500601A1 (en) 2021-05-17
JP2024009834A (ja) 2024-01-23
KR20200118464A (ko) 2020-10-15
IL276584B2 (en) 2024-10-01
UA126746C2 (uk) 2023-01-18
NZ766027A (en) 2026-03-27
JP2021513507A (ja) 2021-05-27
GEP20227407B (en) 2022-08-25
IL276584A (en) 2020-09-30
JOP20200169A1 (ar) 2020-07-07

Similar Documents

Publication Publication Date Title
MA51733A (fr) Composition contraceptive présentant des effets cardiovasculaires réduits
EP3722358A4 (en) COMPOSITION
DK3697376T3 (da) Sammensætning
EP3478482A4 (en) COMPOSITION FOR FORMING DIELECTRIC FILMS
EP3853332C0 (en) COMPOSITION
EP3981255A4 (en) NUTRITIONAL COMPOSITION
EP3882323A4 (en) COMPOSITION
DK3840596T3 (da) Sammensætning
IL262390A (en) Semaglutide in cardiovascular conditions
EP3636081A4 (en) FOOD COMPOSITION
ITUA20162751A1 (it) Composizione secca in polvere
EP3897866C0 (en) ANTIMICROBIAL COMPOSITION
EP3374434C0 (en) CRACK-RESISTANT MICROSURFACING COMPOSITION
DK3459354T3 (da) Glyceridsammensætning
DK3423082T3 (da) Liraglutid ved kardiovaskulære tilstande
EP3675653C0 (fr) Composition antimycotoxine
EP3868869A4 (en) NUTRITIONAL COMPOSITION
DK3623432T3 (da) Sammensætning
EP3846831C0 (en) COMPOSITIONS OF ASSOCIATIONS OF PROBIOTICS
EP3623430C0 (en) COMPOSITION
EP3782632A4 (en) ANTISTRESS COMPOSITION
EP3808785A4 (en) COMPOSITION
DK3576546T3 (da) Probiotisk sammensætning
ES1209313Y (es) Composicion liofilizada
EP3493682C0 (en) COMPOSITION COMPRISING DUDDINGTONIA FLAGRANS